Guardant Health Wins 2026 Prix Galien USA Award for Best Medical Technology for Shield Blood Test
Business Wire•03/11/2026•08:05 ET
0
Key Highlights
- ➤Guardant Health’s Shield wins 2026 Prix Galien USA Best Medical Technology award
- ➤Shield has performed over 200,000 real-world tests
- ➤Shield demonstrates over 90% screening adherence in real-world settings
- ➤Shield is the first FDA-approved blood test for primary colorectal cancer screening
Expert Statements
AmirAli Talasaz, Co-CEO of Guardant Health
“Today’s recognition affirms what Shield was designed to do: improve population health by making colorectal cancer screening more accessible”
AmirAli Talasaz, Co-CEO of Guardant Health
“Built on more than a decade of pioneering, proprietary innovation in blood-based testing, Shield has continually demonstrated its ability to increase screening adherence in real-world settings, helping more people get screened and advancing our mission to close the nation’s colorectal cancer screening gap.”
Guardant Health Wins 2026 Prix Galien USA Award for Best Medical Technology for Shield Blood Test
* Shield blood test for colorectal cancer (CRC) recognized for impact in increasing screening participation for CRC and closing today’s screening gaps
Get started
Create a free account to read the full story.